Compass Therapeutics Stock (NASDAQ:CMPX)

Forecast Revenue Ownership Financials Chart

Previous Close

$3.16

52W Range

$0.87 - $4.08

50D Avg

$2.52

200D Avg

$2.19

Market Cap

$439.74M

Avg Vol (3M)

$837.67K

Beta

1.28

Div Yield

CMPX Company Profile

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Apr 05, 2021

Website

CMPX Performance

CMPX Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	-
Operating Income	$-50.36M	$-41.66M	$-81.88M
Net Income	$-42.49M	$-36.80M	$-82.55M
EBITDA	$-48.47M	$-37.39M	$-29.61M
Basic EPS	$-0.33	$-0.35	$-1.31
Diluted EPS	$-0.33	$-0.35	$-1.31

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
IRON	Disc Medicine, Inc.
JBIO	Jade Biosciences, Inc.
CRNX	Crinetics Pharmaceuticals, Inc.
ANNX	Annexon, Inc.
HOWL	Werewolf Therapeutics, Inc.
LRMR	Larimar Therapeutics, Inc.
EWTX	Edgewise Therapeutics, Inc.
CNTA	Centessa Pharmaceuticals plc
IKNA	Ikena Oncology, Inc.
TRDA	Entrada Therapeutics, Inc.